Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Biologicals. 2019 May 23;60:1–7. doi: 10.1016/j.biologicals.2019.05.005

Table 2.

Identified questions that could be addressed in epidemiological studies on the differences between Pandemrix and Arepanrix and the association with narcolepsy.

• Is there a difference in the background incidence of narcolepsy between the populations that received Pandemrix and Arepanrix that could explain the observed difference in vaccine associated narcolepsy?
• Is there a difference in the expression of the HLA-DQB1*06:02 allele and other HLA types in the populations that received Pandemrix and Arepanrix?
• Was there a difference in the time window between vaccination and infection in populations receiving Pandemrix and Arepanrix?
• Could the risk be assessed at the individual level by comparing the risk of narcolepsy according to timing of vaccination relative to infection (before, same time, or after) and for each individual calculate recent exposure and interaction of the vaccine effect could be assessed?